BioSpace News Archive

Embolization is a minimally invasive procedure that blocks blood flow to a particular area of the body, leading to effective shrinkage of an aneurysm or a tumor.

Pregnancy test is an indicative marker test for determination of pregnancy, which measures the human chorionic gonadotropin in urine samples.

Worldwide, the rising awareness for preventive medicine to prevent bacterial diseases is the foremost factor driving the bacterial vaccines market.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2021.

Kurin Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that July revenues represent their highest monthly total in their history.

Itamar Medical Ltd., a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, reported unaudited financial results for the second quarter of 2021.

Cullinan Oncology, Inc., an oncology company seeking to drive shareholder returns by focusing on the patient, announced its financial results for the second quarter ended June 30, 2021 and reported on recent business highlights.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Ophthalmology Virtual Conference being held August 17, 2021.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results as of and for the second quarter ended June 30, 2021.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported financial results for the second quarter ended June 30, 2021 as well as certain other business highlights.